Quick Answer
Ultragenyx Pharmaceutical Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $673.00 million for the year ending 2025.
- Ultragenyx Pharmaceutical Inc. showed an increase of +20.2% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from Ultragenyx Pharmaceutical Inc.'s annual report (Form 10-K), filed with the SEC on February 18, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 10 years of available data (2016 to 2025), Ultragenyx Pharmaceutical Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 505,915.0%.
- Historical annual values: Fiscal year 2025: $673.00 million | Fiscal year 2024: $560.00 million | Fiscal year 2023: $434.00 million | Fiscal year 2022: $363.33 million | Fiscal year 2021: $351.41 million | Fiscal year 2020: $271.03 million | Fiscal year 2019: $103.71 million | Fiscal year 2018: $51.50 million | Fiscal year 2017: $2.61 million | Fiscal year 2016: $133.0 thousand.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: